Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...

We’re still in the early stages of RSV season, but doctors are already worried about a rise in cases. As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

As of Jan. 20, the CDC reports that RSV activity has peaked in most of the U.S., particularly among young children—a group ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The Health Department of Northwest Michigan is reporting an increase in respiratory illnesses across Antrim, Charlevoix, ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.